NCT05232955 is a clinical trial of PET/MR scanner in Gilles de la Tourette Syndrome, sponsored by Max Planck Institute for Human Cognitive and Brain Sciences.

Who is sponsoring NCT05232955?

NCT05232955 is sponsored by Max Planck Institute for Human Cognitive and Brain Sciences.

What drugs are being tested in NCT05232955?

Interventions in NCT05232955: PET/MR scanner.

What condition does NCT05232955 study?

NCT05232955 studies Gilles de la Tourette Syndrome, Tourette Syndrome.

Is NCT05232955 still recruiting?

NCT05232955 is currently completed. Last updated 1 April 2024.

Last reviewed 2024-04-01 · How we verify

NCT05232955

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Investigations of the Pathophysiology of Gilles de la Tourette Syndrome. Part 1: Simultaneous PET and 3T MRI

Completed Last updated 1 April 2024

What this trial tests

trial testing PET/MR scanner in Gilles de la Tourette Syndrome in 40 participants. Completed in 4 July 2023.

Timeline

4 May 2022

Primary endpoint
6 April 2023

4 July 2023

Quick facts

Lead sponsor	Max Planck Institute for Human Cognitive and Brain Sciences
Status	Completed
Study type	OBSERVATIONAL
Enrollment	40
Start date	4 May 2022
Primary completion	6 April 2023
Estimated completion	4 July 2023
Sites	1 location across Germany

Drugs / interventions tested

PET/MR scanner

Conditions studied

Gilles de la Tourette Syndrome — all drugs for Gilles de la Tourette Syndrome →
Tourette Syndrome — all drugs for Tourette Syndrome →

Sponsor

Max Planck Institute for Human Cognitive and Brain Sciences

Who can join

Adults 18 to 50, any sex, with Gilles de la Tourette Syndrome or Tourette Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Gilles de la Tourette syndrome (GTS; also known as Tourette syndrome) is a congenital neuropsychiatric disorder. Characteristic symptoms are so-called tics-rapid, repetitive movements (motor tics) or vocalizations (vocal tics) that start suddenly without any apparent purpose. Previous research supports the hypothesis of defective regulation (dysregulation) of the dopaminergic system, with particular discussion of dysfunction of tonic/phasic dopamine release or dopaminergic hyperinnervation. Moreover, given the complex interaction of different neurotransmitters, especially in the basal ganglia, it can be assumed that abnormal dopaminergic transmission also affects other transmitter systems, such as glutamate (Glu) or γ-aminobutyrate (GABA). Furthermore, recent results suggest an abnormality in cerebral iron metabolism in GTS. Since iron is accumulated in dopamine vesicles and plays a central role in dopamine synthesis, this observation may also be related to dysfunction of the dopaminergic system. Therefore, in this multimodal study, the investigators aim to combine positron emission tomography (PET), magnetic resonance imaging (MRI), and magnetic resonance spectroscopy (MRS) methods comparing patients with GTS and a control cohort. In Part 1 of this study, MRI and MRS at 3 Tesla are employed to investigate (i) the binding potential of D1 dopamine receptors, (ii) the concentrations of Glu, glutamine and GABA in the corpus striatum and the cortex cingularis anterior and (iii) the subcortical iron concentration.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Abnormalities of iron homeostasis and the dopaminergic system in Tourette syndrome revealed by 7T MRI and PET.
Gkotsoulias DG, Rullmann M, Schmitt S, Bujanow A, et al · · 2025 · cited 3× · PMID 40177529 · DOI 10.1093/braincomms/fcaf104
CRISPR/Cas9 in colorectal cancer: Revolutionizing precision oncology through genome editing and targeted therapeutics.
Alhasso B, Shareef A, Baldaniya L, Oweis R, et al · · 2025 · PMID 40896696 · DOI 10.22038/ijbms.2025.87531.18902

Verify or expand the search:

Other trials of PET/MR scanner

Trials testing the same drug.

NCT03404648 — Staging Prostate Cancer With Hybrid C11-Choline PET/MR and mpMRI · Phase 3 · completed

Other recruiting trials for Gilles de la Tourette Syndrome

Currently open trials in the same condition.

NCT06050369 — Objective Characterizatoion of Repetitive Behaviors · NA · recruiting

Other Max Planck Institute for Human Cognitive and Brain Sciences trials

Trials by the same sponsor.

NCT07501377 — Effects of a 6-months Fiber- and Polyphenol-rich Diet on Brain Inflammatory Processes in Perimenopausal Women Living Wit · NA · recruiting
NCT06116942 — Magnetic Brain Stimulation and Computer-based Motor Training for Rehabilitation After Stroke · NA · recruiting
NCT05233306 — Investigations of the Pathophysiology of Gilles de la Tourette Syndrome. Part 2: 7T MRI · completed
NCT03829189 — High-fiber Diet on the Body and the Brain · NA · completed
NCT06729658 — Dopamine and Brain Computer Interface · EARLY_PHASE1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05232955 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Max Planck Institute for Human Cognitive and Brain Sciences
Last refreshed: 1 April 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05232955.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing